What is Kyntra Bio, Inc.'s market cap?

Kyntra Bio, Inc. (KYNB) has a market capitalization of $28.5M and trades on NASDAQ.

Who are Kyntra Bio, Inc.'s competitors?

Kyntra Bio, Inc.'s key competitors include Bristol Myers Squibb, Geron Corporation, Akebia Therapeutics, Inc., and others. These companies compete in similar markets and product categories.

Who does Kyntra Bio, Inc. partner with?

Kyntra Bio, Inc.'s notable partners include Astellas Pharma Inc., AstraZeneca, Fortis Therapeutics, Inc., and others.

What subsidiaries does Kyntra Bio, Inc. have?

Kyntra Bio, Inc.'s subsidiaries include FibroGen International (Hong Kong) Ltd..

Where is Kyntra Bio, Inc. headquartered?

Kyntra Bio, Inc. is headquartered in United States of America. It has been publicly traded since 2014.

KYN

Kyntra Bio, Inc.

KYNB

Kyntra Bio is a biopharmaceutical company specializing in the development of novel therapies for cancer and anemia.

Market cap

$28.54M-5.9%

Table of contents

Earnings

Q1 2026 report

May 11, 2026

Revenue$3.7MBeat by $2.1M EPS-$3.74Miss by $0.38

Read the full report

Next report

Aug 10, 2026 (In 1 week)

Revenue estimate$2.1M

EPS estimate-$3.18

Competitors

By market cap

Bristol-Myers Squibb$127.75B+32.1%

Ultragenyx Pharmaceutical$2.6B+1.5%

Eton Pharmaceuticals, Inc.$1.2B+188%

Geron$949.5M+29.6%

Akebia Therapeutics$343.4M-63.6%

Fulcrum Therapeutics, Inc.$248.5M-41.0%

Unicycive Therapeutics, Inc.$140.5M+134%

KYN

Kyntra Bio, Inc.$28.5M—

By revenue growth

Geron+537%

Eton Pharmaceuticals, Inc.+79.9%

Ultragenyx Pharmaceutical+13.5%

Bristol-Myers Squibb+1.8%

By net margin

Bristol-Myers Squibb15.01%+3.8pp

Eton Pharmaceuticals, Inc.-9.5%+2.7pp

Ultragenyx Pharmaceutical-90.92%+2.2pp

Geron-682.47%+436pp

Profile

Kyntra Bio is a biopharmaceutical company specializing in the development of novel therapies for cancer and anemia. The company focuses on advancing antibody-drug conjugates for oncology and small molecule inhibitors for rare disease indications. Its core value proposition lies in addressing high unmet medical needs through first-in-class treatments and companion diagnostic biomarkers.

Competitive position

Kyntra Bio is a clinical-stage developer in oncology while maintaining a commercial-stage presence in anemia through global licensing partnerships.

GeographiesUnited States, Europe, Japan, Canada, Mexico

Customer segmentsHealthcare Providers, Pharmaceutical Companies

Business modelR&D, Licensing, IP Monetization

SuppliersContract Manufacturing Organizations (CMOs), Academic Research Institutions, Raw Material Suppliers

CustomersPharmaceutical Distributors, Hospitals, Specialty Pharmacies, Collaboration Partners

CountryUnited States of America

Listed2014

CEOThane Wettig

SectorHealthcare

IndustryMedical - Pharmaceuticals

Websitekyntrabio.com

FilingsSEC EDGAR

Questions, answered.

What is Kyntra Bio, Inc.'s market cap?: Kyntra Bio, Inc. (KYNB) has a market capitalization of $28.5M and trades on NASDAQ.
Who are Kyntra Bio, Inc.'s competitors?: Kyntra Bio, Inc.'s key competitors include Bristol Myers Squibb, Geron Corporation, Akebia Therapeutics, Inc., and others. These companies compete in similar markets and product categories.
Who does Kyntra Bio, Inc. partner with?: Kyntra Bio, Inc.'s notable partners include Astellas Pharma Inc., AstraZeneca, Fortis Therapeutics, Inc., and others.
What subsidiaries does Kyntra Bio, Inc. have?: Kyntra Bio, Inc.'s subsidiaries include FibroGen International (Hong Kong) Ltd..
Where is Kyntra Bio, Inc. headquartered?: Kyntra Bio, Inc. is headquartered in United States of America. It has been publicly traded since 2014.